(Q45040155)

8 December 2017

Insulin binding capacity in patients changed from conventional to highly purified insulins. An indicator of likely response (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A562300

11 July 2022

author name string

B. E. Mustaffa

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A562300

11 July 2022

P. R. Daggett

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A562300

11 July 2022

J. D. Nabarro

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A562300

11 July 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=562300

11 July 2022

publication date

1 August 1977

1 reference

8 December 2017

1 reference

8 December 2017

13

1 reference

8 December 2017

4

1 reference

8 December 2017

311-315

1 reference

https://scigraph.springernature.com/pub.10.1007/bf01223271

8 December 2017

0 references

cites work

Single-peak insulin in the treatment of insulin-induced fat atrophy

1 reference

12 December 2020

Hazards of monocomponent insulins.

1 reference

12 December 2020

Letter: Clinical aspects of "monocomponent" insulin in diabetes

1 reference

12 December 2020

Effect of "fractionated" insulins on total plasma insulin binding capacity and insulin requirements in severe diabetes

1 reference

12 December 2020

The immunogenic properties of highly purified insulin preparations: The clinical importance of insulin-binding antibodies

1 reference

12 December 2020

Clinical Aspects of Insulin–Antigenicity

1 reference

12 December 2020

Neutralization of the biologic activity of human serum bound insulin by potent insulin antisera

1 reference

12 December 2020

Insulin antagonists, insulin antibodies and insulin resistance

1 reference

12 December 2020

The immunogenicity of insulin preparations

1 reference

12 December 2020

Quantitation of free, total, and antibody-bound insulin in insulin-treated diabetics

1 reference

12 December 2020

Treatment of insulin lipoatrophy with monocomponent insulin.

1 reference

12 December 2020

Clinical trial with monocomponent lente insulins. Preliminary report

1 reference

12 December 2020

Insulin antibodies and the control of diabetes

1 reference

12 December 2020

Comparative Trials with Monocomponent (MC) and Monospecies (MS) Pork Insulins in the Treatment of Diabetes mellitus. Influence on Antibody Levels, on Insulin Requirement and on Some Complications

1 reference

12 December 2020

Insulin antibody formation. I. The influence of age, sex, infections, insulin dosage and regulation of diabetes

1 reference

12 December 2020

MULTIPLICITY OF INSULIN-BINDING ANTIBODIES IN HUMAN SERA. PRESENCE OF ANTIBODY ACTIVITY IN GAMMA-, BETA-2A-, AND BETA-2M-GLOBULINS

1 reference

12 December 2020

Distribution of injected insulin and insulin-antibody complexes in normal and insulin-immunized animals.

1 reference

12 December 2020

Antigenicity of “Monocomponent” Pork Insulin in Diabetic Subjects

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01223271

1 reference

Dimensions Publication ID

8 December 2017

0 references

1 reference